152 related articles for article (PubMed ID: 10651730)
1. Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia.
Denzlinger C; Bowen D; Benz D; Gelly K; Brugger W; Kanz L
Br J Haematol; 2000 Jan; 108(1):93-5. PubMed ID: 10651730
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
Robak T; Szmigielska-Kapłon A; Urbańska-Ryś H; Chojnowski K; Wrzesień-Kuś A
Neoplasma; 2003; 50(3):172-5. PubMed ID: 12937849
[TBL] [Abstract][Full Text] [Related]
3. Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia.
Anargyrou K; Vaiopoulos G; Terpos E; Tsironi M; Konstantopoulos K; Samarkos M; Meletis J
Haematologia (Budap); 2002; 32(2):169-73. PubMed ID: 12412738
[TBL] [Abstract][Full Text] [Related]
4. [Low dose melphalan therapy was effective in an elderly patient with MDS-AML].
Ontachi Y; Yamauchi H; Takami A; Asakura H; Nakao S
Nihon Ronen Igakkai Zasshi; 2001 May; 38(3):405-8. PubMed ID: 11431899
[TBL] [Abstract][Full Text] [Related]
5. Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure.
Stratmann J; van Kann E; Rummelt C; Koschade S; Röllig C; Lübbert M; Schaich M; Parmentier S; Sebastian M; Chromik J; Becker von Rose A; Ballo O; Steffen B; Serve H; Brandts C; Shaid S
Leuk Res; 2019 Oct; 85():106192. PubMed ID: 31445469
[TBL] [Abstract][Full Text] [Related]
6. Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.
Malladi RK; Peniket AJ; Norton AE; Campbell AJ; Collins GP; Samol J; Eagleton H; Miller E; Morgenstern G; Jones J; Keen-Mcguire A; Barnardo M; Littlewood TJ
Eur J Haematol; 2004 Aug; 73(2):85-92. PubMed ID: 15245506
[TBL] [Abstract][Full Text] [Related]
7. Low-dose melphalan in elderly acute myeloid leukaemia: complete remissions but resistant relapse with therapy-related karyotypes.
Kerr R; Cunningham J; Bowen DT
Leukemia; 2000 May; 14(5):953. PubMed ID: 10803536
[No Abstract] [Full Text] [Related]
8. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
Tauro S; Craddock C; Peggs K; Begum G; Mahendra P; Cook G; Marsh J; Milligan D; Goldstone A; Hunter A; Khwaja A; Chopra R; Littlewood T; Peniket A; Parker A; Jackson G; Hale G; Cook M; Russell N; Mackinnon S
J Clin Oncol; 2005 Dec; 23(36):9387-93. PubMed ID: 16314618
[TBL] [Abstract][Full Text] [Related]
9. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
[TBL] [Abstract][Full Text] [Related]
10. Long term remission of acute myeloid leukaemia with trilineage myelodysplasia treated solely with low dose cytarabine.
Jack FR; Summerfield GP
Clin Lab Haematol; 1994 Jun; 16(2):197-200. PubMed ID: 7955930
[No Abstract] [Full Text] [Related]
11. Chemotherapy of secondary leukemias.
Visani G; Pagano L; Pulsoni A; Tosi P; Piccaluga PP; Pastano R; Grafone T; Malagola M; Isidori A; Tura S
Leuk Lymphoma; 2000 May; 37(5-6):543-9. PubMed ID: 11042514
[TBL] [Abstract][Full Text] [Related]
12. Hypoplastic myelodysplastic syndrome transformed in acute myeloid leukemia after androgens and cyclosporin. A treatment.
Gologan R; Ostroveanu D; Dobrea C; Gioadă L
Rom J Intern Med; 2003; 41(4):447-55. PubMed ID: 15526527
[TBL] [Abstract][Full Text] [Related]
13. Remission induction in elderly acute myeloid leukemia by low-dose melphalan.
Gologan R; Ostroveanu D; Gioada L; Iacob V
Rom J Intern Med; 2003; 41(1):67-73. PubMed ID: 15529587
[No Abstract] [Full Text] [Related]
14. Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression.
Brandwein JM; Kassis J; Leber B; Hogge D; Howson-Jan K; Minden MD; Galarneau A; Pouliot JF
Br J Haematol; 2014 Dec; 167(5):664-70. PubMed ID: 25160658
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
[TBL] [Abstract][Full Text] [Related]
16. [Therapy-related acute leukaemia and myelodysplastic syndrome].
Díaz Beveridge R; Aparicio Urtasun J
An Med Interna; 2003 May; 20(5):257-68. PubMed ID: 12831302
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment with low dose Ara-C in de novo acute myeloid leukemia with trilineage myelodysplasia.
Kawano F; Nishimura Y; Tsukamoto A; Satoh M; Sanada I; Shido T
Int J Hematol; 1992 Feb; 55(1):101-2. PubMed ID: 1581580
[No Abstract] [Full Text] [Related]
18. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
[TBL] [Abstract][Full Text] [Related]
19. Combined low-dose cytarabine, melphalan and mitoxantrone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Yamauchi T; Negoro E; Arai H; Ikegaya S; Takagi K; Takemura H; Inai K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Anticancer Res; 2007; 27(4C):2635-9. PubMed ID: 17695426
[TBL] [Abstract][Full Text] [Related]
20. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
